Skip to main content
Johnson & JohnsonPartnership

J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up to

Source: Autobound Signal API · 88 signals tracked for Johnson & Johnson · updated

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.

What happened

Johnson & Johnson announced it would enter into an agreement with Blackstone Life Sciences for $750 million in multi-year financing dedicated to the development of OLN324.

Source

Article excerpt

by Sneha S K Johnson & Johnson JNJ.N announced on Monday that it has reached an agreement to acquire Texas-based biotech company Ollin Biosciences for up to 3.33 billion dollars, expanding its portfolio of treatments for eye diseases. Ollin’s experimental eye disease treatment, OLN324, will help J&J strengthen its presence in a field where its footprint remains limited, despite its major contact lens business. OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two major causes of vision loss. According to J&J estimates, these two conditions together affect more than 40 million people worldwide. "Johnson & Johnson has built a strong reputation in ophthalmology through its surgical equipment and eye care products, primarily ACUVUE contact lenses, which makes this strategic alliance entirely logical," said Trung Huynh, an analyst at RBC Capital Markets. In a recent early-phase comparative study, the drug showed faster and greater improvements in eye structure, as well as superior visual gains in both diabetic macular edema (DME) and wet AMD, compared to Roche's ROPC.S Vabysmo, Ollin stated. The acquisition includes an upfront payment of 2.2 billion dollars and potential milestone payments linked to regulatory approvals and commercialization of up to 1.13 billion dollars, J&J specified. The transaction is expected to...

Keep reading with a free account

The rest of this article, and every signal for Johnson & Johnson, is in your free account.

Extracted from this sentence

J&J also announced that it would enter into a separate agreement with Blackstone Life Sciences for multi-year financing of 750 million dollars dedicated to the advanced development of OLN324, in exchange for certain payments and royalties.

Extracted by Autobound

From the Signal API record
Event
Partnership

What this signalsA new partnership often opens integration and co-selling work.

More partnership signals at other companies

The full record

From the Signal API record

Extraction

Confidence
88%
Detected
Nov 16, 2026
signal_type
news
signal_subtype
partners_with

Use this data

Get every partnership signal for Johnson & Johnson and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Johnson & Johnson this week?”

  2. Send it to your own tools

    The Signal API returns partnership signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/5cd9f2b6-8898-0265-a812-f628a99b1801 returns this record as JSON. POST /v1/companies/enrich returns every signal for jnj.com.

{
  "signal_id": "5cd9f2b6-8898-0265-a812-f628a99b1801",
  "signal_type": "news",
  "signal_subtype": "partners_with",
  "detected_at": "2026-11-16T13:41:00+00:00",
  "company": {
    "name": "Johnson & Johnson",
    "domain": "jnj.com"
  },
  "data": {
    "url": "https://www.boursorama.com/bourse/actualites-amp/j-j-conclut-un-accord-de-rachat-de-2-2-milliards-de-dollars-avec-la-societe-de-biotechnologie-specialisee-dans-les-maladies-oculaires-ollin-biosciences-20d248095316b2f6fe432a937527f46c",
    "title": "J&J to acquire eye disease-focused biotech firm Ollin Biosciences for up to - Boursorama",
    "excerpt": "by Sneha S K Johnson & Johnson JNJ.N announced on Monday that it has reached an agreement to acquire Texas-based biotech company Ollin Biosciences for up to 3.33 billion dollars, expanding its portfolio of treatments for eye diseases. Ollin’s experimental eye disease treatment, OLN324, will help J&J strengthen its presence in a field where its footprint remains limited, despite its major contact lens business. OLN324 is being developed to treat diabetic macular edema (DME) and wet age-related macular degeneration (AMD), two major causes of vision loss. According to J&J estimates, these two conditions together affect more than 40 million people worldwide. \"Johnson & Johnson has built a strong reputation in ophthalmology through its surgical equipment and eye care products, primarily ACUVUE contact lenses, which makes this strategic alliance entirely logical,\" said Trung Huynh, an analyst at RBC Capital Markets. In a recent early-phase comparative study, the drug showed faster and greater improvements in eye structure, as well as superior visual gains in both diabetic macular edema (DME) and wet AMD, compared to Roche's ROPC.S Vabysmo, Ollin stated. The acquisition includes an upfront payment of 2.2 billion dollars and potential milestone payments linked to regulatory approvals and commercialization of up to 1.13 billion dollars, J&J specified. The transaction is expected to...",
    "summary": "Johnson & Johnson announced it would enter into an agreement with Blackstone Life Sciences for $750 million in multi-year financing dedicated to the development of OLN324.",
    "planning": true,
    "image_url": "https://www.boursorama.com/bundles/boursoramaui/images/news/trading-news-6.jpg",
    "confidence": 0.88,
    "published_at": "2026-11-16T13:41:00Z",
    "article_sentence": "J&J also announced that it would enter into a separate agreement with Blackstone Life Sciences for multi-year financing of 750 million dollars dedicated to the advanced development of OLN324, in exchange for certain payments and royalties.",
    "related_company_name": "Blackstone Life Sciences",
    "related_company_domain": "blackstone.com"
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.